Molecular Templates

moleculartemplates.com

Molecular Templates (MTEM) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary Engineered Toxin Body (ETB) platform. MTEM’s first immunotoxin, MT-3724, is in clinical development for non-Hodgkin’s lymphoma. Pipeline products for additional oncology targets are being advanced toward clinical development. For more information, please visit MTEM’s website at www.mtem.com.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

TAKEDA TO ACQUIRE ADAPTATE BIOTHERAPEUTICS TO DEVELOP NOVEL GAMMA DELTA (ΓΔ) T CELL ENGAGER THERAPIES TARGETING SOLID TUMORS

Takeda | January 11, 2022

news image

Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Adaptate Biotherapeutics a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are des...

Read More

GINKGO BIOWORKS ANNOUNCES PARTNERSHIP WITH TOTIENT TO IDENTIFY NEUTRALIZING ANTIBODIES AGAINST COVID-19

Ginkgo Bioworks | September 11, 2020

news image

Today, Ginkgo Bioworks announced a partnership with Totient, an AI-driven drug discovery company emerging from stealth, to rapidly identify neutralizing antibodies against COVID-19. Through this partnership, Totient will leverage Ginkgo's bioengineering platform to express and screen thousands of antibody candidates with the aim of identifying broadly neutralizing therapeutic antibodies against COVID-19 for further development. Totient leverages tertiary lymphoid structures (TLSs) to identif...

Read More

MOLECULIN ANNOUNCES DISCOVERY OF SIGNIFICANT IN VITRO ACTIVITY AGAINST SARS-COV-2

Moleculin | September 29, 2020

news image

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Independent laboratory testing of the new drug candidate, called "WP1096," has now repea...

Read More

Industry Outlook

ENVEDA BIOSCIENCES UNVEILS NEW AI ALGORITHM TO UNLOCK NATURE’S CHEMICAL CODE

Businesswire | June 26, 2023

news image

Enveda Biosciences, a biotechnology company discovering new medicines from natural sources, released the details of one of its foundational AI models, MS2Mol, in a pre-print posted on ChemRxiv. MS2Mol is designed to predict the structure of metabolites, which are the building blocks and breakdown products of the cell. Despite their essential role in all cell processes, it is estimated that less than 1% of all naturally-occurring metabolites are known to science. The ability of MS2Mol to ra...

Read More
news image

Cell and Gene Therapy

TAKEDA TO ACQUIRE ADAPTATE BIOTHERAPEUTICS TO DEVELOP NOVEL GAMMA DELTA (ΓΔ) T CELL ENGAGER THERAPIES TARGETING SOLID TUMORS

Takeda | January 11, 2022

Takeda Pharmaceutical Company Limited announced the exercise of its option to acquire Adaptate Biotherapeutics a UK company focused on developing antibody-based therapeutics for the modulation of variable delta 1 (Vδ1) gamma delta (γδ) T cells. Through the acquisition, Takeda will obtain Adaptate’s antibody-based γδ T cell engager platform, including pre-clinical candidate and discovery pipeline programs. Adaptate’s γδ T cell engagers are des...

Read More
news image

GINKGO BIOWORKS ANNOUNCES PARTNERSHIP WITH TOTIENT TO IDENTIFY NEUTRALIZING ANTIBODIES AGAINST COVID-19

Ginkgo Bioworks | September 11, 2020

Today, Ginkgo Bioworks announced a partnership with Totient, an AI-driven drug discovery company emerging from stealth, to rapidly identify neutralizing antibodies against COVID-19. Through this partnership, Totient will leverage Ginkgo's bioengineering platform to express and screen thousands of antibody candidates with the aim of identifying broadly neutralizing therapeutic antibodies against COVID-19 for further development. Totient leverages tertiary lymphoid structures (TLSs) to identif...

Read More
news image

MOLECULIN ANNOUNCES DISCOVERY OF SIGNIFICANT IN VITRO ACTIVITY AGAINST SARS-COV-2

Moleculin | September 29, 2020

Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting significant unmet needs in the treatment of tumors and viruses, announced that its research team has discovered that a molecule within its portfolio of antimetabolites has displayed significant in vitro antiviral activity against SARS-CoV-2. Independent laboratory testing of the new drug candidate, called "WP1096," has now repea...

Read More
news image

Industry Outlook

ENVEDA BIOSCIENCES UNVEILS NEW AI ALGORITHM TO UNLOCK NATURE’S CHEMICAL CODE

Businesswire | June 26, 2023

Enveda Biosciences, a biotechnology company discovering new medicines from natural sources, released the details of one of its foundational AI models, MS2Mol, in a pre-print posted on ChemRxiv. MS2Mol is designed to predict the structure of metabolites, which are the building blocks and breakdown products of the cell. Despite their essential role in all cell processes, it is estimated that less than 1% of all naturally-occurring metabolites are known to science. The ability of MS2Mol to ra...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us